<figure><img src="https://reader.miniflux.app/proxy/EVMory1Wv-mD8ndZwMBHVIBamTuyKbP9B3koG0fwTbQ=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wOC9MaXR0bGUtdmFjY2luZS10aGF0LWNvdWxkLTY1MngxMDI0LmpwZw==" alt="A man is reading to a little boy. The book is &#34;The Little Vaccine That Could&#34;, and he&#39;s up to the part where the vaccine is saying, &#34;I think I can, I think I can.&#34; (Cartoon by Hilda Bastian.)" width="232" height="364" srcset="https://reader.miniflux.app/proxy/EVMory1Wv-mD8ndZwMBHVIBamTuyKbP9B3koG0fwTbQ=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wOC9MaXR0bGUtdmFjY2luZS10aGF0LWNvdWxkLTY1MngxMDI0LmpwZw== 652w, https://reader.miniflux.app/proxy/kXSARrKtnPD7BmMNHVlemTr1wQW57jIKtHSCQDA7ZmA=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wOC9MaXR0bGUtdmFjY2luZS10aGF0LWNvdWxkLTE5MXgzMDAuanBn 191w, https://reader.miniflux.app/proxy/hctrRduFad-vSDex6eWFzD7M2ZFeOIT_HkAV78GITrE=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wOC9MaXR0bGUtdmFjY2luZS10aGF0LWNvdWxkLTc2OHgxMjA2LmpwZw== 768w, https://reader.miniflux.app/proxy/ZFXMSTOEd8N_Hkai5xJeP07BLp9oWpJ9KIQ4NuPimNE=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wOC9MaXR0bGUtdmFjY2luZS10aGF0LWNvdWxkLTk3OHgxNTM2LmpwZw== 978w, https://reader.miniflux.app/proxy/zRseO_fnonKFFDmop1SdARSgU5bSbn3Q7Q1_n27mui0=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wOC9MaXR0bGUtdmFjY2luZS10aGF0LWNvdWxkLTEzMDR4MjA0OC5qcGc= 1304w, https://reader.miniflux.app/proxy/R_jk4EsNjqO8KHNiXV-fQ6es1_dKxCJ84q1FTu4ldu8=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wOC9MaXR0bGUtdmFjY2luZS10aGF0LWNvdWxkLmpwZw== 1340w" sizes="(max-width: 232px) 100vw, 232px" loading="lazy"/></figure>







<p>This month, we got news that another couple of next generation vaccines are heading into human trials, both with national research agency support – an intranasal vaccine from the US, and a pancoronavirus vaccine from France. The US government’s Project NextGen announced that a billion dollars is available to support a network of vaccine trials. And according to a company report, the first public results for a clinical trial of a pancoronavirus vaccine could be around the corner.</p>



<p>Those highlights and more below, broken down into news on US Project NextGen, and 3 categories of next-generation Covid vaccines (<a href="#definitions">definitions below</a>).</p>



<p> </p>



<h2 id="contents"></h2>







<ul><li>Update on US <a href="#nextgen">Project NextGen</a></li><li><a href="#mucosal">Mucosal</a> vaccine news</li><li>Covid-19 <a href="#panSARS2">“variant-proof”</a> vaccine news</li><li><a href="#pancoronavirus">Pancoronavirus</a> vaccine news</li><li><em>Addendum 1:</em> Table of <a href="#mucosaltable">mucosal vaccines</a> in clinical trials</li><li><em>Addendum 2: </em>Table of <a href="#pantable">pancoronavirus vaccines</a> with results</li><li><em>Addendum 3:</em> <a href="#definitions">Definitions</a> of vaccine types</li></ul>



<h2 id="nextgen"></h2>







<h4>Update on US Project NextGen</h4>







<p>First, a recap. In May, the US government-funded Project NextGen was announced, with US$5 billion for public partnerships to develop better Covid vaccines and treatments (more on this in <a href="https://absolutelymaybe.plos.org/2023/05/30/progress-on-next-generation-covid-vaccines-update-7/#nextgen" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">my June update</a>). At the end of June, <a href="https://www.nytimes.com/2023/06/26/health/covid-vaccines-nextgen.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">journalists reported</a> that about 70 companies had responded (not only on vaccines). Back then, it was expected that there would be eventually be support for early-to-mid-stage clinical trials of up to 10 vaccines, with shared protocols and systems. </p>



<p>The first funding recipients <a href="https://www.hhs.gov/about/news/2023/08/22/funding-1-billion-vaccine-clinical-trials-326-million-new-monoclonal-antibody-100-million-explore-novel-vaccine-therapeuti-technologies.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">were announced</a> earlier this week, although we still don’t know which vaccines are likely to get the boost. US$1 billion was awarded to 4 companies that run clinical trials, to be ready to run phase 2b vaccine trials. The aim is to “speed the development of new vaccine candidates, providing a network of at-the-ready trials with the flexibility to pivot to the most promising new vaccines as they mature. The public can expect to see clinical trials for new vaccine candidates targeting longer-lasting protection against future variants as early as this winter under Project NextGen.”</p>



<p>Phase 1 trials are first-in-human trials, testing safety and helping establish dosages. Phase 2 trials are mid-stage – bigger than phase 1, but not as big as a phase 3 trials for establishing efficacy. Phase 2b trials are small efficacy trials, midway between phases 2 and 3. That means Project NextGen isn’t going to get a vaccine all the way through to FDA approval: Manufacturers will need to do that bit of heavy lifting.</p>



<p>What vaccines could be ready for phase 2b in the US by the end of year? There are more than half a dozen mucosal vaccines from US developers that are at least as far along as fully-recruited phase 1 trials in <a href="#mucosaltable">the table below</a>. There’s not enough published data from most of them though, so it’s hard to know which might be going well enough to justify an efficacy trial. Nor do we know which groups want to run their trial with Project NextGen. </p>



<p>One stands out, though – NDV-HXP-S, the vaccine that inspired the cartoon at the head of this post. It’s developed at Mt Sinai in New York, and is available non-profit for development in lower income countries – 4 have used it.</p>



<p>Some background on this vaccine (from a previous post): It couples old school, widely accessible technology – the vaccine can be mass-produced in eggs the way flu vaccines are – with a major advance in the way the virus spike is modified. It’s a viral vector vaccine based on the Newcastle Disease virus (NDV) and the Hexapro spike (HXP-S), which is a modification of the spike protein that could make this vaccine particularly potent. A license from the University of Texas at Austin developers of HXP-S is available to low and middle countries without royalties, and the Mt-Sinai-developed NDV platform is also non-profit. There’s a must-read article on this vaccine by Carl Zimmer <a href="https://www.nytimes.com/2021/04/05/health/hexapro-mclellan-vaccine.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">in the <em>New York Times</em></a>.</p>



<p>Last year, Mount Sinai <a href="https://www.mountsinai.org/about/newsroom/2022/mount-sinai-announces-the-formation-of-castlevax-inc-a-clinical-stage-infectious-diseases-company-developing-novel-vaccines-and-therapeutics-targeting-pandemic-threats-and-diseases-of-unmet-medical-need" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">announced</a> the formation of Castlevax to develop this vaccine commercially. Although we’ve only seen press release reports for them, there are phase 1 trial results for an intranasal version in the US, as well as phase 2 trial results for the intranasal version developed in Mexico. It’s not the only possibility, but it’s definitely one to look out for in the news.</p>







<p><em><a href="#contents">Back to contents</a></em></p>



<h2 id="mucosal"></h2>







<h4>Mucosal vaccine news</h4>







<p>One of the vaccines headed into clinical trials is an intranasal vax developed by the US National Institutes of Health (NIH). The development was announced by <a href="https://www.nhpr.org/health/2023-08-17/dartmouth-hitchcock-covid19-coronavirus-vaccine-nasal" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Dartmouth</a>, who will be working on the vaccine and its trials, and <a href="https://exothera.world/press-releases-nih-and-exothera-collaborate-to-produce-gmp-intranasal-vaccine-against-sars-cov-2-for-clinical-trial-in-africa-and-us/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Exothera</a>, a manufacturer from Belgium that has been commissioned to produce enough of the vaccine for the trials. The trials will be phase 1/2, in Africa and the US.</p>



<p>Researchers at the NIH have been involved in the development of several vaccines with published results, but I haven’t been able to pin down for sure which vaccine this is – or if anything has been published about it. The Exothera press release says it’s based on adenovirus 4, but also mentions live, non-replicating virus. I’ll be on the lookout for more details.</p>



<p>Someone on Mastodon, whose post I lost track of (apologies!), alerted me to a <a href="https://www.wfmz.com/health/health-beat/health-beat-new-covid-vaccine-nasal-drops/article_992bd12c-15f1-11ee-9564-435e2d8c7e11.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">media report in the US</a> that developers of the Washington University in St Louis (WUSL) intranasal vaccine expect it to “be ready to be presented to the FDA in the United States by the end of the year.” I’m not sure what that means, but it seems to me it could be early steps in the process, not an application for approval.</p>



<p>This vaccine is an adenoviral vector vaccine, developed in the US under the name ChAd-SARS-CoV-2-S. It was used by Bharat Biotech in India to develop a vaccine called iNCOVACC there – authorized for use there in September 2022 (making it the third mucosal vaccine to be rolled out globally). However, the amount of trial evidence accepted in India isn’t necessarily going to be enough in the US. Bharat Biotech published results of their phase 3 trial <a href="https://www.nature.com/articles/s41541-023-00717-8" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">this month</a> – in January, those results were released <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4342771" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">in a preprint</a>, so it’s been included in the last few updates here.</p>



<p>We’re still waiting to hear from the FDA on specific requirements for approving Covid vaccines – the <a href="https://www.federalregister.gov/documents/2023/03/13/2023-05094/guidance-documents-related-to-coronavirus-disease-2019-covid-19" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">emergency use authorization expires</a> later this year. I had a look at the <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">most recently FDA-approved vaccine</a> for non-pregnant adults: That was approved with a placebo-controlled phase 3 trial with 25,000 participants. The phase 3 trial for iNCOVACC had only around 3,000 people, with fewer than 200 in a control group.</p>



<p>This month, the developers from WUSL released <a href="https://www.researchsquare.com/article/rs-3185983/v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">a fourth report</a> of preclinical results. In that study, hamsters vaccinated with ChAd-SARS-CoV-2-S were in contact with both vaccinated and unvaccinated hamsters. The developers concluded that while the intranasal vaccine didn’t completely stop virus transmission, it had the potential to interrupt transmission – the animals that showed signs of the virus didn’t have a high enough viral load to transmit it to others in turn.</p>



<p>(This vaccine is listed in <a href="#mucosaltable">the table below</a> as BBV154 (iNCOVACC).)</p>







<p><em><a href="#contents">Back to contents</a></em></p>



<h2 id="panSARS2"></h2>







<h4>Covid-19 “variant-proof” vaccine news</h4>







<p>I didn’t see new developments or results for vaccines in this category. Gritstone Bio <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-reports-second-quarter-2023-financial-results-and" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">reported</a> to investors, however, that they expect to release more results from their phase 1 trials later this year. This is a self-amplifying mRNA vaccine that has 3 phase 1 trials in progress, including with some NIH funding. More on what we know so far in <a href="https://absolutelymaybe.plos.org/2023/06/29/this-months-progress-in-next-generation-covid-vaccines-update-8/#panSARS2" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">my Update 8</a>. </p>







<p><em><a href="#contents">Back to contents</a></em></p>



<h2 id="pancoronavirus"></h2>







<h4>Pancoronavirus vaccine news</h4>







<p>As far as I know, there are still only 3 vaccines in this category in phase 1 trials: an mRNA vaccine from DIOSynvax (Cambridge University, UK); a virus-like particle vaccine (eVLP) from VBI Vaccines (Canada); and a protein subunit vaccine from the Walter Reed Army Institute of Research (USA). A VBI Vaccines <a href="https://www.vbivaccines.com/press-releases/vbi-vaccines-reports-second-quarter-2023-financial-results/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">company report said</a> they expect to have interim results of their phase 1 trial by the end of September – if so, that’s the first time we’ll see trial results for a pancoronavirus vaccine.</p>



<p>As mentioned above, a fourth pancoronavirus vaccine is heading into a phase 1 clinical trial, expected to start in early 2024. Developed by France’s INSERM, the national health and medical research institution, it has now been named PanCov. INSERM has <a href="https://linkinvax.com/wp-content/uploads/2023/07/PR_GTP_Bioways-Fareva-EngV6-eng.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">partnered with LinKinVax</a> to manufacture the protein subunit vaccine for the trial. The records I have for this vaccine are <a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/PanCov%20(CD40.CoV2)%20Vaccine%20Research%20Unit%2FINSERM%2FUPEC%2FLinKinVax/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">here</a> – and you can see the slides of a presentation the developers made to the WHO in 2022 <a href="https://cdn.who.int/media/docs/default-source/blue-print/yves-levy_t-cells_whoconsultation_pan-sarbecovirus_28jan2022.pdf?sfvrsn=98371feb_9" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">here</a>.</p>



<p>This month there were preclinical results for 2 pancoronavirus vaccines, both from China:</p>



<ul><li>There were results in mice for <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202301034" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">an intranasal vaccine</a> from Sun Yat-Sen University. It is a mosaic nanoparticle vaccine – a method for carrying fragments from multiple different versions of coronaviruses. This one includes RBD fragments of 6 SARS-CoV-2 variants – the original, Delta, and 4 Omicron variants. Mice developed signs of immune response to more than 6 Covid variants, as well as original SARS.</li><li>Results in mice for <a href="https://www.tandfonline.com/doi/full/10.1080/22221751.2023.2244084" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">a protein subunit vaccine</a> with an adjuvant, from Fudan University. The mice developed signs of immune response to SARS-CoV-2 variants, original SARS, and other coronaviruses, including MERS. This was the fourth set of results in my database from this group.</li></ul>







<p><em><a href="#contents">Back to contents</a></em></p>



<h2 id="mucosaltable"></h2>







<h4><em>Addendum 1: </em>Table of mucosal vaccines in clinical trials</h4>







<p><em>*  Indicates new entry since my previous update post.</em></p>







<p><em>Note: Where there is a link to “All records” for a vaccine, that’s in my public Zotero collection for the vaccine, and it may include non-mucosal studies for that vaccine. <em><em>Notes</em> <em>on that collection are <a href="https://absolutelymaybe.plos.org/2022/01/26/boosters-and-mixed-schedules-covid-vaccines-at-the-2-year-mark-part-1/#collection" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">here</a>.</em></em> <em>For details on how I track Covid vaccine progress to maintain that collection, see my <a href="https://absolutelymaybe.plos.org/2022/02/28/tracking-the-covid-vaccine-race-in-the-wild-first-2-years-a-process-story/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">background post</a>.</em></em></p>







<figure><table><thead><tr><th>Vaccine, type, manufacturer</th><th>Mucosal version(s)</th><th>Phase 1 to 2 clinical trials</th><th>Phase 3+ trial(s)</th><th>Phase 3+ efficacy or immunogenicity results</th></tr></thead><tbody><tr><td>ACM-001<br/><em>Protein subunit</em><br/><br/><em>ACM Biolabs (Singapore/Switzerland)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/ACM-001%20-%20ACM%20Biolabs/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05385991" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.</td><td></td><td></td></tr><tr><td>Ad5-nCoV (Convidecia Air)<br/><em>Viral vector</em> <em>(adenovirus)</em><br/><br/><em>CanSino (China)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/Ad5-nCov%20CanSino/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Inhaled through the mouth using a nebulizer.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04552366" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>. <strong><a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00087-X/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05043259" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1/2</a>. <strong><a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4000565" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (plus <strong><a href="https://www.medrxiv.org/content/10.1101/2022.07.26.22278072v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">second later preprint</a></strong>).<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05330871" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a> (aged 6-17 years).</td><td>10,420 people in China (<a href="https://clinicaltrials.gov/ct2/show/NCT05204589" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>).<br/><strong><a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00350-X/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/>1,350 people (<a href="https://clinicaltrials.gov/ct2/show/NCT05442684" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>).<br/><br/>540 people, in Malaysia (<a href="https://clinicaltrials.gov/ct2/show/NCT05517642" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>).<br/><br/>904 people in China (<a href="https://www.chictr.org.cn/hvshowproject.aspx?id=148875" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 4</a>).<br/><strong><a href="https://www.medrxiv.org/content/10.1101/2022.03.08.22271816v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/>360 people (<a href="https://clinicaltrials.gov/ct2/show/NCT05303584" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 4</a>).</td><td>Comparison after 2-dose course of inactivated vax: Convidecia injection vs inhaled, protein subunit, or CoronaVac booster (<strong><a href="https://www.medrxiv.org/content/10.1101/2022.03.08.22271816v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 4 results</a></strong>). Both injected &amp; inhaled Convidecia had stronger impact on signs of immunity than the others; response after inhaled version was slower but longer-lasting than injected (which peaked then declined from day 14), better for Omicron though not as good for original virus. No measure of mucosal immunity used.</td></tr><tr><td>Ad5-triCoV/Mac &amp; ChAd-triCoV/Mac<br/><em>Viral vector (adenovirus)</em><br/><br/>McMaster University/Canadian Institutes of Health Research (Canada)<br/></td><td>Aerosol.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05094609" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><br/></td><td></td><td></td></tr><tr><td>AdCOVID<br/><em>Viral vector</em> <em>(adenovirus)</em><br/><br/><em>AltImmune (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/AdCOVID%20Altimmune/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04679909" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>. <strong><a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-update-adcovidtm-phase-1-clinical-trial" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> – press release only.<br/><br/><em>Discontinued after phase 1.</em></td><td></td><td> </td></tr><tr><td>AdS+N<br/><em>Viral vector (adenovirus)</em><br/><br/><em>ImmunityBio (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/AdS%2BN%20(hAd5%20S-Fusion%20%2B%20N-ETSD)%20ImmunityBio,Mucosal%20vaccine/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)<br/><br/></td><td>Intranasal, oral capsule, or sublingual.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04732468" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a> (oral).<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT04591717" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a> (sublingual).</td><td></td><td></td></tr><tr><td>Avacc 10<br/><em>Protein subunit</em><br/><br/><em>Intravacc (Netherlands)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/Avacc%2010%20-%20Intravacc/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05604690" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.</td><td></td><td></td></tr><tr><td>bacTRL-Spike-1<br/><em>Live attenuated</em><br/><br/><em>Symvivo (Canada)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/bacTRL-Spike-1%20Symvivo/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Oral.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04334980" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.</td><td></td><td></td></tr><tr><td>BBV154 (iNCOVACC)<br/><em>Viral vector</em> <em>(adenovirus)</em><br/><br/><em>Bharat Biotech (India)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/BBV154%20Bharat/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)<br/><br/>* This vaccine is ChAd-SARS-CoV-2-S<br/><em>Washington University in St Louis (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/ChAd-SARS-CoV-2-S%20(BBV154)%20Washington%20Uni%20St%20Louis%2FPrecision%20Virologics%2FBharat/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)<br/><br/></td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04751682" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><br/><a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=59902" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.<br/><br/>Small amount of data from these trials in the <a href="https://www.bharatbiotech.com/images/incovacc/incovacc-smpc.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">drug product information</a>.<br/><br/><a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=59216" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2/3</a>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05639998" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.</td><td>In India, 2-dose course of BBV154 vs 2-dose course of injected Covaxin inactivated vaccine (<a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=65443" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a> – and <a href="https://clinicaltrials.gov/ct2/show/NCT05522335" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">here</a>).<br/>* <strong><a href="https://www.nature.com/articles/s41541-023-00717-8" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results </a></strong>(previously <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4342771" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">a preprint</a>).<br/><br/><em>See also the <a href="https://www.bharatbiotech.com/images/incovacc/incovacc-smpc.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">drug product information</a>.</em><br/><br/>875 people in India, booster trial (<a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=65451" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>).</td><td>2,971 previously unvaxed people were assigned for the intranasal iNCOVACC, 161 for injected Covaxin. This trial did not aim to assess disease outcomes. It took place during the first Omicron wave.<br/><br/>Signs of immune response were higher for iNCOVACC than Covaxin. <br/><br/>Adverse events rate very low (5% local and 3% systemic) – lower than for comparison group.</td></tr><tr><td>BV-AdCoV-1<br/><em>Viral vector (adenovirus)</em><br/><br/><em>Wuhan BravoVax</em><br/><em>(China)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/BV-AdCoV-1%20Wuhan%20BravoVax/items/NLEUGD29/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Inhaled through the mouth using a nebulizer.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05706324" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.</td><td></td><td></td></tr><tr><td>ChAdOx1<br/><em>Viral vector (adenovirus)</em><br/><br/><em>Oxford University (UK)</em><br/><em>(This is the AstraZeneca vax)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/ChAdOx1%20nCov-19%20Oxford-AstraZeneca,Mucosal%20vaccine/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04816019" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05007275" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><br/><strong><a href="https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00480-7/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.</td><td></td><td></td></tr><tr><td>CoV2-OGEN1<br/><em>Protein subunit</em><br/><br/><em>US Specialty Formulations/VaxForm</em> <em>(USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/CoV2-OGEN1%20USSF%2FVaxform/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Oral.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04893512" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/>(Fully recruited, final dose in November 2022.)</td><td></td><td></td></tr><tr><td>COVI-VAC<br/><em>Live attenuated</em><br/><br/><em>Codagenix (USA, with the Serum Institute of India)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/COVI-VAC%2FCoviLiv%20Codagenix/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><br/><a href="https://clinicaltrials.gov/ct2/show/NCT04619628" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><a href="https://www.prnewswire.com/news-releases/codagenix-announces-safety-and-immunogenicity-data-from-phase-1-covid-19-intranasal-vaccine-trial-and-intent-to-progress-to-phase-23-studies-301382120.html?tc=eml_cleartime" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Press release</a> stating successful (without data) and progressing to phase 2/3.<br/><strong><a href="https://europepmc.org/article/PMC/PMC8644858" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (conference abstract) and in <a href="https://codagenix.com/codagenix-intranasal-covid-19-vaccine-shows-potent-cellular-immune-response-against-conserved-viral-proteins-indicating-potential-for-immunogenicity-against-omicron-and-future-variants-in-phase-1-dat/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">press release</a>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05233826" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a> (booster).</td><td>Phase 2/3, as part of the <a href="https://www.isrctn.com/ISRCTN15779782" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">WHO Solidarity Trial for Vaccines</a> in <a href="https://cvd-mali.org/en/solidarity-trial-vaccines-enters-major-new-phase-recruiting-now/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Mali</a>. (<a href="https://cdn.who.int/media/docs/default-source/blue-print/who-covid-2019_solidarityvaccinetrial_14-june-2021_clean_for-registry.pdf?sfvrsn=77b2110a_11" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Protocol</a>.)</td><td></td></tr><tr><td>CVXGA1-001<br/><em>Viral vector (parainfluenza)</em><br/><br/><em>CyanVac/Blue Lake Tech (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/CVXGA1-001%20-%20Uni%20of%20Georgia%2FCyanVac/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04954287" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><a href="https://clinicaltrials.gov/ct2/show/NCT05736835" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.</td><td></td><td></td></tr><tr><td>DNS1-RBD (Pneucolin)<br/><em>Viral vector (influenza)</em><br/><br/><em>Beijing Wantai BioPharm (China)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/dNS1-RBD%20Beijing%20Wantai%20Biological%20Pharmacy%20Enterprise/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04809389" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><a href="https://clinicaltrials.gov/ct2/show/NCT05200741" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.<br/><strong><a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00131-X/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Joint results</a></strong>.</td><td>30,990 participants in Colombia, Philippines, South Africa, Vietnam.<br/><strong><a href="https://www.researchsquare.com/article/rs-2407050/v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/>5,400 participants in Ghana (<a href="https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=17163" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>).</td><td>Comparison of 2 doses of intranasal vaccine 14 days apart, with placebo control, during circulation of Omicron. Included &gt;13,000 previously unvaccinated people.<br/><br/>Efficacy shown 90 days after 2nd dose. There was some decline at 180 days.<br/><br/><em>Efficacy against symptomatic Covid:</em><br/>No previous vax: 55.2% (CI 13.8 to 76.7)<br/>Inactivated: 38.2% (CI -49.2 to 74.4)<br/>Viral vector: 39.9% (CI -16.7 to 69.1)<br/>mRNA: 10.1% (CI -45.9 to 44.5)<br/><br/><em>Efficacy against severe Covid:</em><br/>No previous vax: 66.7% (CI 8.3 to 87.9)<br/>Inactivated: 54.6% (CI -47.3 to 86.0)<br/>Viral vector: 50.0% (CI -6.8 to 76.6)<br/>mRNA: 19.5% (CI -39.2 to 53.4)<br/><br/><em>Efficacy against hospitalization:</em><br/>100% (CI -9.2 to 100)<br/><br/>Adverse events were very low – similar to placebo. Less than 8% of people had a runny and/or blocked nose or sore throat.</td></tr><tr><td>GAM-COVID-VAC (rAd26-S – Sputnik Light)<br/><em>Viral vector (adenovirus)</em><br/><br/><em>Gamaleya Research Institute (Russia)</em></td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05248373" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1/2</a><br/></td><td>7,000 participants in Russia (<a href="https://grls.rosminzdrav.ru/CiPermitionReg.aspx?PermYear=0&amp;DateInc=&amp;NumInc=&amp;DateBeg=&amp;DateEnd=&amp;Protocol=&amp;RegNm=&amp;Statement=&amp;ProtoId=&amp;idCIStatementCh=&amp;Qualifier=&amp;CiPhase=&amp;RangeOfApp=&amp;Torg=&amp;LFDos=&amp;Producer=%d0%9d%d0%b0%d1%86%d0%b8%d0%be%d0%bd%d0%b0%d0%bb%d1%8c%d0%bd%d1%8b%d0%b9+%d0%b8%d1%81%d1%81%d0%bb%d0%b5%d0%b4%d0%be%d0%b2%d0%b0%d1%82%d0%b5%d0%bb%d1%8c%d1%81%d0%ba%d0%b8%d0%b9+%d1%86%d0%b5%d0%bd%d1%82%d1%80+%d1%8d%d0%bf%d0%b8%d0%b4%d0%b5%d0%bc%d0%b8%d0%be%d0%bb%d0%be%d0%b3%d0%b8%d0%b8+%d0%b8+%d0%bc%d0%b8%d0%ba%d1%80%d0%be%d0%b1%d0%b8%d0%be%d0%bb%d0%be%d0%b3%d0%b8%d0%b8&amp;Recearcher=&amp;sponsorCountry=&amp;MedBaseCount=&amp;CiType=&amp;PatientCount=&amp;OrgDocOut=2&amp;Status=1%2c2%2c3%2c4%2c&amp;NotInReg=0&amp;All=0&amp;PageSize=8&amp;order=numperm&amp;orderType=desc&amp;pagenum=1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a> or phase 2/3 – not clear).</td><td></td></tr><tr><td>Mambisa<br/><em>Protein subunit</em><br/><br/><em>Centre for Genetic Engineering &amp; Biotechnology </em>(<em>CIGB) (Cuba)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/Mambisa%20CIBG%2FBioCubaFarma/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal drops.</td><td><a href="https://rpcec.sld.cu/en/trials/RPCEC00000345-En" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1/2</a>.<br/><br/><a href="https://rpcec.sld.cu/en/trials/RPCEC00000382-En" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1/2</a>.<br/><strong><a href="https://www.prensa-latina.cu/2022/04/27/candidato-vacunal-mambisa-de-cuba-cumple-expectativas-de-estudios" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (report of a conference presentation).<br/><br/><a href="https://rpcec.sld.cu/en/trials/RPCEC00000398-En" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.</td><td></td><td></td></tr><tr><td>MV-014-212<br/><em>Viral vector</em><br/><em>(RSV)</em><br/><br/><em>Meissa Vaccines (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/MV-014-212%20Meissa%20Vaccines/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal drops or spray. </td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04798001" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><strong><a href="https://www.businesswire.com/news/home/20211028005281/en/Meissa-Announces-Positive-Preliminary-Clinical-Data-on-Safety-and-Immunogenicity-of-Intranasal-COVID-19-Vaccine" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (press release).</td><td></td><td></td></tr><tr><td>MVA-SARS-2ST<br/><em>Viral vector (MVA)</em><br/><br/><em>German Centre for Infection Research (DZIF)/IDT Biologika</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/MVA-SARS-2S%20German%20Centre%20for%20Infection%20Research%20(DZIF)%2FIDT%20Biologika/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Inhalation.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05226390" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.</td><td></td><td></td></tr><tr><td>NDV-HXP-S<br/><em>Viral vector (Newcastle Disease Virus)</em><br/><br/><em>Castlevax/Icahn Mt Sinai</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/NDV-HXP-S%20-%20Icahn%20School%20of%20Medicine%20Mt%20Sinai/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)<br/></td><td>Intranasal.</td><td><a href="https://www.clinicaltrials.gov/study/NCT05181709" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><strong><a href="https://www.mountsinai.org/about/newsroom/2023/promising-results-of-next-generation-intranasal-covid-booster-vaccine-implications-for-infection-prevention-and-transmission" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (press release).</td><td></td><td></td></tr><tr><td>Patria (NDV-HXP-S/AVX-COVID-12-HEXAPRO)<br/><em>Viral vector (Newcastle Disease Virus)</em><br/><br/><em>Laboratorio Avi-Mex (Mexico)</em><br/>(All records on <a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/NDV-HXP-S%2FPatria%20(AVX-COVID-12-HEXAPRO)%20Avimex/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Patria</a>, see NDV-HXP-S above for early development.)<br/><br/></td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04871737" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><strong><a href="https://www.nature.com/articles/s41541-023-00662-6" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05205746" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.<br/><strong><a href="https://avimex.com.mx/noticias-y-eventos/45" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (press release).</td><td></td><td><br/></td></tr><tr><td>PRAK-03202<br/><em>Protein subunit</em><br/><br/><em>Oravax (USA) [Oravax was established by OraMed (Israel) to develop this vaccine, using Premas Biotech’s PRAK-03202 and their oral vaccine technology]</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/PRAK-03202%20Oravax%2FOramed/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a> on oral PRAK-03202, and <a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/PRAK%E2%88%9203202%20Premas%20Biotech/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">on intramuscular version</a>)</td><td>Oral.</td><td><a href="https://sanctr.samrc.ac.za/TrialDisplay.aspx?TrialID=5673" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a> (in South Africa).<br/><strong><a href="https://www.prnewswire.com/news-releases/oramed-subsidiary-oravax-reports-positive-preliminary-phase-1-data-for-its-oral-covid-19-vaccine-301643522.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results </a></strong>(press release only).</td><td></td><td></td></tr><tr><td>Razi Cov Pars<br/><em>Protein subunit</em><br/><br/><em>Razi Vaccine &amp; Serum Research Institute (Iran)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/Razi%20Cov%20Pars%20-%20Razi%20Vaccine%20%26%20Serum%20Research%20Institute/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal (third dose after 2 injections).</td><td><a href="https://www.irct.ir/trial/52975" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><strong><a href="https://www.mdpi.com/2076-393X/11/2/455" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/><a href="https://www.irct.ir/trial/55238" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.<br/><br/><a href="https://www.irct.ir/trial/61378" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1 to 2</a> (in 12-17 year-olds).</td><td>41,128 people in Iran, comparing the 3-dose course to 2-dose inactivated Sinopharm Beijing vax (<a href="https://www.irct.ir/trial/58143" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>). (Press report of <strong><a href="https://www.farsnews.ir/en/news/14001123000446/Razi-Insie-Chief-Underlines-High-Efficiency-f-Iran-Made-Razi-Cv-Pars" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">results</a></strong>, in the <a href="https://www.tasnimnews.com/fa/news/1400/11/20/2659676/%D8%A7%D8%AB%D8%B1%D8%A8%D8%AE%D8%B4%DB%8C-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D8%B1%D8%A7%D8%B2%DB%8C-3-%D8%A8%D8%B1%D8%A7%D8%A8%D8%B1-%D8%B3%DB%8C%D9%86%D9%88%D9%81%D8%A7%D8%B1%D9%85-%D8%A7%D8%B3%D8%AA-%D8%A7%D9%85%DA%A9%D8%A7%D9%86-%D8%A7%D8%B3%D8%AA%D9%81%D8%A7%D8%AF%D9%87-%D8%A7%D8%B2-%D8%AF%D9%88%D8%B2-%D8%A7%D8%B3%D8%AA%D9%86%D8%B4%D8%A7%D9%82%DB%8C-%D8%A8%D9%87-%D8%B9%D9%86%D9%88%D8%A7%D9%86-%D8%AF%D9%88%D8%B2-%D8%B3%D9%88%D9%85-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D9%87%D8%A7%DB%8C-%DA%A9%D8%B1%D9%88%D9%86%D8%A7" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">first 24,000</a> participants.)</td><td>There were no hospitalizations for Covid in the Razi Cov Pars group and 5 in the Sinopharm group. The rate of Covid was reportedly more than twice as high in the Sinopharm group.</td></tr><tr><td>SC-Ad6-1<br/><em>Viral vector (adenovirus)</em><br/><br/><em>Moat Bio/Tetherex (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/SC-Ad6-1%20Mayo%20Clinic%2FTetherex%20Pharmaceuticals" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal and inhaled.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04839042" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/>Trial expanded to add an inhaled version (from 130 to 190 people). Results so far briefly mentioned in <a href="https://www.prnewswire.com/news-releases/moat-biotechnology-raises-6-5m-in-first-close-for-intranasalinhaled-covid-19-vaccine-301849665.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">press release</a>.</td><td></td><td></td></tr><tr><td>(Unnamed)<br/><em>Inactivated bacteria</em><br/><br/><em>DreamTec (Hong Kong)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/Unnamed%20-%20DreamTec/search/dreamtec/titleCreatorYear/item-list" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Oral.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05057923" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><a href="https://clinicaltrials.gov/ct2/show/NCT05158855" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><a href="https://clinicaltrials.gov/ct2/show/NCT05239923" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><br/><em>Note: </em>An article of <a href="https://www.mdpi.com/2076-393X/10/11/1852" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">preclinical results has been retracted</a> over lack of ethics committee approval. </td><td></td><td></td></tr><tr><td>VXA-CoV2-1/VXA-CoV2-1.1-S<br/><em>Viral vector</em><br/><em>(adenovirus)</em><br/><br/><em>Vaxart (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/VXA-CoV2-1%20-%20Vaxart/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Tablets.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04563702" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><strong><a href="https://www.medrxiv.org/content/10.1101/2022.07.16.22277601v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05067933" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>. (Recruiting: started October 1, 2021.)<br/><strong><a href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-top-line-phase-ii-clinical-study-data" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (press release).</td><td>Omicron adaptation was developed for an Omicron challenge trial, originally <a href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-top-line-phase-ii-clinical-study-data" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">planned</a> for second half of 2023.<br/><br/>This vax is<a href="https://www.proactiveinvestors.co.uk/companies/news/1009235/hvivo-manufactures-omicron-human-challenge-study-1009235.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer"> now on hold</a>, as Vaxart is trying to develop an oral pan-betacoronavirus vaccine.</td><td><br/></td></tr></tbody></table></figure>







<p><em><a href="#contents">Back to contents</a></em></p>



<h2 id="pantable"></h2>







<h4>Addendum 2: <strong><em>Pancoronavirus vaccines with preclinical results</em></strong></h4>







<p>* <em>Indicates new entry since previous update post. </em>  </p>







<figure><table><thead><tr><th>Developer<br/><em>Country</em><br/><br/><em>Vaccine name</em></th><th>Type of:<br/><br/>Vaccine<br/><br/><em>Coronavirus</em></th><th>Preclinical results</th><th>Clinical trial status</th></tr></thead><tbody><tr><td>California Institute of Technology (Caltech)<br/><em>USA</em><br/><br/><em>Mosaic-8b</em></td><td>Protein subunit<br/><br/><em>Beta</em></td><td><a href="https://www.science.org/doi/10.1126/science.abf6840" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.biorxiv.org/content/10.1101/2023.02.24.529520v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.sciencedirect.com/science/article/pii/S107476132200560X" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.science.org/doi/10.1126/science.abq0839" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate, non-primate</a></td><td></td></tr><tr><td>Codiak<br/><em>USA</em><br/><br/><em>exoVACC Pan Beta Coronavirus</em></td><td>Protein subunit<br/><br/><em>Beta</em><br/></td><td><a href="https://www.sciencedirect.com/science/article/pii/S0092867421007972" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Article on development</a><br/><br/>Non-primate (<a href="https://s3.us-east-1.amazonaws.com/codiak-assets.investeddigital.com/publications/Codiak-WVIC-Poster-for-exoVACC-120221-FINAL.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">conference slides</a>)<br/><br/>Non-primate<br/>(<a href="https://s3.us-east-1.amazonaws.com/codiak-assets.investeddigital.com/publications/Codiak-World-Vaccine-Congress-April-20-2022-Final-V2.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">conference slides</a>)</td><td><em>(This company <a href="https://cases.stretto.com/codiak" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">began proceedings</a></em><br/><em>in bankruptcy court. See news.)</em></td></tr><tr><td>DIOSynvax<br/><em>UK</em><br/><br/><em>DIOS-CoVax/<br/>pEVAC-PS</em></td><td>mRNA<br/><br/><em>Sarbeco</em></td><td><a href="https://www.researchsquare.com/article/rs-995273/v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td><a href="https://www.isrctn.com/ISRCTN87813400" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1 trial</a> (incl. protocol)<br/><em>(Up to 36 participants)</em><br/>Began <a href="https://www.cam.ac.uk/stories/DIOSCoVax_safetytrial" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">December 2021</a>.<br/>Fully recruited.<br/><a href="https://www.nihr.ac.uk/news/trials-launched-for-revolutionary-needle-free-coronavirus-vaccine/33575" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Expanded </a>to another city – no trial register entry found.</td></tr><tr><td>Duke University<br/><em>USA</em><br/><br/><em>RBD–scNP</em></td><td>Protein subunit<br/><br/><em>Beta</em><br/></td><td><a href="https://www.nature.com/articles/s41586-021-03594-0" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.nature.com/articles/s41467-022-33985-4" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate, non-primate</a><br/><br/><a href="https://www.biorxiv.org/content/10.1101/2023.05.22.540829v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>Francis Crick Institute<br/><em>UK</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit with DNA boost<br/><br/><em>All</em></td><td><a href="https://www.science.org/doi/10.1126/scitranslmed.abn3715" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>Fudan University<br/><em>China</em><br/><br/><em>HR1LS</em></td><td>Protein subunit<br/><br/><em>Sarbeco</em></td><td><a href="https://www.nature.com/articles/s41422-022-00612-2" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate, non-primate</a><br/><br/><a href="https://www.nature.com/articles/s41422-022-00631-z" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.pnas.org/doi/full/10.1073/pnas.2221713120" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/>* <a href="https://www.tandfonline.com/doi/full/10.1080/22221751.2023.2244084" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>INSERM Vaccine Research Institute/LinKinVax<br/><em>France</em><br/><br/><em>PanCov</em> (<em>CD40.CoV2)</em></td><td>Protein subunit<br/><em>Sarbeco</em></td><td><a href="https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00243-2/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.nature.com/articles/s41467-021-25382-0" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate, non-primate</a><br/><br/><a href="https://elifesciences.org/articles/75427" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.croiconference.org/wp-content/uploads/sites/2/posters/2023/CROI-Poster-Nguema020223-133204312648122137.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> <em>(conference poster)</em></td><td></td></tr><tr><td>Oragenics/Inspirevax/ National Research Council of Canada<br/><em>USA, Canada</em><br/><br/><em>NT-CoV2-1</em></td><td>Protein subunit<br/>(Intranasal)<br/><br/><em>All</em></td><td><a href="https://www.nature.com/articles/s41598-021-01363-7" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> <em>(original vax)</em><br/><br/><a href="https://www.nature.com/articles/s41598-022-13819-5" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> <em>(original vax)</em></td><td></td></tr><tr><td>Osivax<br/><em>France</em><br/><br/>OVX033</td><td>Protein subunit<br/><br/><em>Sarbeco</em></td><td><a href="https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188605/full" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>Pennsylvania State University<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit<br/><br/><em>All</em></td><td><a href="https://onlinelibrary.wiley.com/doi/10.1002/adfm.202206055" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>Scripps Research Institute<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit<br/><br/><em>Beta</em></td><td><br/><br/><a href="https://www.science.org/doi/10.1126/sciadv.abj3107" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>SK Bioscience/ Uni of Washington/Uni of North Carolina at Chapel Hill<br/><em>South Korea, USA</em><br/><br/><em>GBP511</em></td><td>Protein subunit<br/><br/><em>Sarbeco</em></td><td><a href="https://www.science.org/doi/epdf/10.1126/scitranslmed.adg7404" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate, non-primate</a> <em>(testing Covid vaccine GBP510 against other sarbecoviruses)</em><br/></td><td><em>(<a href="https://cdn.who.int/media/docs/default-source/blue-print/dev_sk-biosciences_king_whoconsultation_pan-sarbecovirus_28jan2022.pdf?sfvrsn=53bc4a23_7" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">More on plans for adapting this vaccine</a> – GBP510 authorized as SKYCovione.)</em></td></tr><tr><td>Stanford University<br/><em>USA</em><br/><br/><em>DCFHP-alum</em></td><td>Protein subunit<br/><br/><em>Sarbeco</em></td><td><a href="https://www.nature.com/articles/s41467-023-37417-9" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.biorxiv.org/content/10.1101/2023.06.27.546764v2" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/></td><td></td></tr><tr><td>* Sun Yat-Sen University<br/><em>China</em><br/><br/><em>Unnamed)</em></td><td>Protein subunit<br/><br/><em>Sarbeco</em></td><td><a href="https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202301034" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>University of California Irvine<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Viral vector<br/><br/><em>Beta</em></td><td><a href="https://www.biorxiv.org/content/10.1101/2023.05.24.541850v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.biorxiv.org/content/10.1101/2023.05.23.542024v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> (mucosal)<br/><br/><em>(There was also a paper about this vaccine’s development <a href="https://journals.aai.org/jimmunol/article/206/11/2566/234252/Genome-Wide-B-Cell-CD4-and-CD8-T-Cell-Epitopes" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">in 2021</a>.)</em></td><td></td></tr><tr><td>University of North Carolina at Chapel Hill<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Viral vector<br/><br/><em>Sarbeco</em></td><td><a href="https://www.biorxiv.org/content/10.1101/2022.11.28.518175v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>University of Toronto<br/><em>Canada</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit<br/><br/><em>Sarbec</em>o</td><td><a href="https://www.cell.com/cell-reports/fulltext/S2211-1247(23)00402-3" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>University of Wisconsin-Madison (PanCorVac)<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit<br/><br/><em>All</em></td><td><a href="https://www.nature.com/articles/s42003-021-02128-8" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00523-0/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.researchsquare.com/article/rs-3088907/v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/></td><td></td></tr><tr><td>VBI Vaccines<br/><em>Canada</em><br/><br/><em>VBI-2901</em></td><td>eVLP<br/><br/><em>All</em></td><td><a href="https://www.biorxiv.org/content/10.1101/2021.09.28.462109v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.vbivaccines.com/press-releases/new-data-and-progress-of-vbi-2900-coronavirus-program/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> (Press release)<br/></td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05548439" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1 trial</a><br/><em>(103 participants)</em><br/>Began October 2022.<br/>Fully recruited.<br/>(<a href="https://cdn.who.int/media/docs/default-source/blue-print/dev_vbi-vaccines_whoconsultation_pan-sarbecovirus_28jan2022.pdf?sfvrsn=2b17ebb1_12" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Further background info</a>.)</td></tr><tr><td>Walter Reed Army Institute of Research (WRAIR)<br/><em>USA</em><br/><br/><em>SpFN</em> <em>1B-06-PL</em></td><td>Protein subunit<br/><br/><em>Beta</em></td><td><a href="https://www.nature.com/articles/s41541-021-00392-7" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.nature.com/articles/s41541-021-00414-4" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01639-9" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> (incl RFN)<br/><br/><a href="https://www.nature.com/articles/s41541-023-00638-6" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.science.org/doi/10.1126/scitranslmed.abi5735" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.mdpi.com/2076-393X/10/5/717" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00128-3" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a> (with J&amp;J vax)</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04784767" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1 trial</a><br/><em>(29 participants)</em><br/>Began April 2021.<br/>Results <a href="https://www.defenseone.com/technology/2021/12/us-army-creates-single-vaccine-effective-against-all-covid-sars-variants/360089/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">described</a> as “positive” – no data reported yet.<br/><a href="https://cdn.who.int/media/docs/default-source/blue-print/9.-modjarrad_vaccine-strategies_r-d-who-consultation_march-25-2020.pdf?sfvrsn=b7d46cdf_7" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Additional detail</a> on phase 1 trial.</td></tr><tr><td>Walter Reed Army Institute of Research (WRAIR)<br/><em>USA</em><br/><br/><em>RFN</em></td><td>Protein subunit<br/><br/><em>Beta</em></td><td><a href="https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01639-9" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> (incl SpFN)<br/><br/><a href="https://www.pnas.org/doi/10.1073/pnas.2106433118" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a></td><td></td></tr><tr><td>Yale University<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>mRNA<br/><br/><em>All</em></td><td><a href="https://www.nature.com/articles/s41467-022-30878-4" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.biorxiv.org/content/10.1101/2022.05.07.491038v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>Yale University/Xanadu Bio<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit, intranasal booster<br/><br/><em>Sarbeco</em></td><td><a href="https://www.science.org/doi/10.1126/science.abo2523" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr></tbody></table></figure>







<p><em><a href="#contents">Back to contents</a></em></p>







<h2 id="definitions"></h2>







<h4><em>Addendum 3:</em> Definitions of vaccine types</h4>







<ul><li>Mucosal vaccines: These enter the body the way the virus does – through mucosal tissues. It’s hoped that provides defence against infection. They can be administered via different routes – squirts or drops in the nose, inhaled through the mouth through a nebulizer (similar to an asthma medication), or in tablet, capsule, or sublingual form.</li><li>Pan-SARS-CoV-2 or “variant-proof” vaccines: These aim to provide protection against any variant of the coronavirus that causes Covid-19 – including future variants.</li><li>Pancoronavirus can be targeted to:<ul><li>the “subgroup” the 2 SARS viruses came from (the sarbecovirus subgenus),</li><li>coronaviruses from the next level up (the genus, betacoronavirus, which includes lethal diseases like MERS, as well as common cold viruses), or</li><li>the whole coronavirus family – it has 4 genuses, including betacoronavirus and alphacoronavirus (with more common cold viruses).</li></ul></li></ul>



<p>I classify a vaccine as a pancoronavirus one when the developers are explicitly targeting coronaviruses more broadly than SARS-CoV-2, and have tested for signs of response to non-SARS-CoV-2 coronavirus(es) (or clearly plan to).</p>







<p><em><a href="#contents">Back to contents</a></em></p>







<p><em>You can keep up with my work at my newsletter, <a href="https://hildabastian.wordpress.com/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Living With Evidence</a>. And I’m active on Mastodon: <a href="https://mastodon.online/@hildabast" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">@hildabast@mastodon.online</a> </em></p>







<p>~~~~</p>







<p><em>For details on how I track Covid vaccine progress, see my <a href="https://absolutelymaybe.plos.org/2023/05/01/a-process-update-on-covid-vaccine-tracking/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">background post</a>.</em> <em>Notes</em> <em>on my collection of studies are <a href="https://absolutelymaybe.plos.org/2022/01/26/boosters-and-mixed-schedules-covid-vaccines-at-the-2-year-mark-part-1/#collection" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">here</a>. The collection is in a public Zotero library you can dig into <a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">here</a>.</em></p>



<p><strong><em>Previous update posts on next generation Covid vaccines:</em></strong></p>



<ol><li>Mucosal vaccines (<a href="https://absolutelymaybe.plos.org/2022/03/30/the-race-to-reduce-covid-19-transmission-an-update-on-66-intranasal-6-oral-vaccines/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">March 2022</a>)</li><li>Pan-SARS-Cov-2 and pancoronavirus (<a href="https://absolutelymaybe.plos.org/2022/07/09/front-runners-in-the-race-for-variant-proof-and-all-coronavirus-vaccines/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">July 2022</a>)</li><li>Mucosal vaccines (<a href="https://absolutelymaybe.plos.org/2022/07/31/next-generation-covid-vaccine-update-intranasal-other-mucosal-vaxes/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">July 2022</a>)</li><li>Mucosal vaccines (<a href="https://absolutelymaybe.plos.org/2022/09/29/intranasal-co-a-very-big-month-for-mucosal-covid-vaccines/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">September 2022</a>)</li><li>Mucosal vaccines (<a href="https://absolutelymaybe.plos.org/2023/04/21/progress-on-intranasal-oral-covid-vaccines-plus-a-us-government-funding-boost/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">April 2023</a>)</li><li>Pancoronavirus vaccines (<a href="https://absolutelymaybe.plos.org/2023/04/26/pancoronavirus-vaccines-update-lots-of-preclinical-results-another-trial-underway/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">April 2023</a>)</li></ol>



<p><strong><em><a href="https://absolutelymaybe.plos.org/?post_tag=covid-19-vaccine-race" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer"><br/></a></em></strong><em><a href="https://absolutelymaybe.plos.org/?post_tag=covid-19-vaccine-race" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All my Absolutely Maybe Covid-19 vaccine posts</a></em></p>



<p><em><a href="https://absolutelymaybe.plos.org/?category=covid-19" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All previous Covid-19 posts at Absolutely Maybe</a></em></p>



<p><em>My posts</em> <em><a href="https://www.theatlantic.com/author/hilda-bastian/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">at The Atlantic</a>, </em><a href="https://www.wired.com/author/hilda-bastian/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer"><em>at WIRED</em></a><em>, and debunking posts <a href="http://hildabastian.net/index.php/covid-19" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">at my personal website</a>.</em></p>



<p><em>Disclosures: My interest in Covid-19 vaccine trials is as a person worried about the virus, as my son is immunocompromised: I have no financial or professional interest in the vaccines. I have worked for an institute of the NIH in the past, but not the one working on vaccines (<a href="https://www.niaid.nih.gov/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">NIAID</a>). <a href="https://blogs.plos.org/absolutely-maybe/about-hilda-bastian/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">More about me</a>.</em></p>



<p><em>The cartoons are my own <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">(CC BY-NC-ND license)</a></em>. <em>(More cartoons at <a href="http://statistically-funny.blogspot.com/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Statistically Funny</a>.)</em></p>







<p></p>

<p>The post <a href="https://absolutelymaybe.plos.org/2023/08/25/more-next-generation-covid-vaccines-are-heading-into-clinical-trials-update-10/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">More Next Generation Covid Vaccines Are Heading Into Clinical Trials (Update 10)</a> appeared first on <a href="https://absolutelymaybe.plos.org" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Absolutely Maybe</a>.</p>
